Mesoblast

Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting
Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting
BioSpace
Mesoblast
remestemcel-L
FDA
graft vs host disease
Flag link:
Mesoblast's CEO takes 30% pay cut to fund 3rd shot at cell therapy approval
Mesoblast's CEO takes 30% pay cut to fund 3rd shot at cell therapy approval
Fierce Biotech
Mesoblast
cell therapy
FDA
Pharma CEOs
executive compensation
Flag link:
FDA Decisions 2023: Sandoz, Gilead Sciences and More
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Flag link:
FDA Blocks Mesoblast Cell Therapy Again, Asks for More Data
FDA Blocks Mesoblast Cell Therapy Again, Asks for More Data
BioSpace
Mesoblast
remestemcel-L
FDA
graft vs host disease
cell therapy
Flag link:
FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
Yahoo/Reuters
Mesoblast
FDA
cell therapy
bone marrow transplants
remestemcel-L
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission
2 years after rejection, Mesoblast touts long-term cell therapy survival data as key to FDA resubmission
Fierce Biotech
Mesoblast
FDA
cell therapy
remestemcel-L
graft vs host disease
Flag link:
Mesoblast considers plans for COVID treatment after Novartis exits deal
Mesoblast considers plans for COVID treatment after Novartis exits deal
Biopharma Reporter
Mesoblast
Novartis
clinical trials
COVID-19
Flag link:
Mesoblast pummelled as Novartis exits COVID deal
Mesoblast pummelled as Novartis exits COVID deal
Pharmaforum
Novartis
Mesoblast
stem cells
remestemcel-L
COVID-19
Flag link:
New Mesoblast Data Offers Hope for High-Risk Heart Patients
New Mesoblast Data Offers Hope for High-Risk Heart Patients
BioSpace
Mesoblast
rexlemestrocel-L
chronic heart failure
clinical trials
Flag link:
Mesoblast’s COVID-19 Respiratory Therapy Hits Another Snag on Route to Potential EUA
Mesoblast’s COVID-19 Respiratory Therapy Hits Another Snag on Route to Potential EUA
BioSpace
Mesoblast
COVID-19
Emergency Use Authorization
respiratory therapy
Flag link:
Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Seeking Alpha
Mesoblast
clinical trials
remestemcel-L
COVID-19
Flag link:
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
Endpoints
Mesoblast
FDA
clinical trials
rexlemestrocel-L
Flag link:
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
BioSpace
Novartis
Mesoblast
remestemcel-L
COVID-19
ARDS
clinical trials
Flag link:
Mesoblast hit by FDA rejection, request to run another trial
Mesoblast hit by FDA rejection, request to run another trial
Fierce Biotech
Mesoblast
cell therapy
clinical trials
remestemcel-L
graft vs host disease
FDA
Flag link:
Go or no go? A quiet month ahead for US approval verdicts
Go or no go? A quiet month ahead for US approval verdicts
EP Vantage
FDA
Bristol-Myers Squibb
CC-486
AML
Mallinckrodt
terlipressin
Mesoblast
Ryoncil
Flag link:
Mesoblast scores FDA committee's backing for cell therapy despite some early worries
Mesoblast scores FDA committee's backing for cell therapy despite some early worries
Fierce Pharma
Mesoblast
cell therapy
FDA
Ryoncil
graft vs host disease
Flag link:
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents
Fierce Pharma
Mesoblast
FDA
cell therapy
drug manufacturing
Flag link:
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Forbes
Mesoblast
Australia
clinical gtrials
ARDS
COVID-19
stem cells
remestemcel-L
Flag link:
3 Biotech Stocks That Soared Last Week
3 Biotech Stocks That Soared Last Week
Motley Fool
Acadia Pharmaceuticals
Nuplazid
Mesoblast
Grunenthal
MPC-06-ID
Kodiak Sciences
age-related macular degeneration
Flag link:

Pages